Drug Metabolism refers to the biochemical processes by which a drug is transformed within the body. This intricate process primarily occurs in the liver and involves a series of enzymatic reactions aimed at converting drugs into metabolites that can be easily excreted from the body. The primary goal of drug metabolism is to facilitate the elimination of drugs from the system while often making them more water-soluble for efficient excretion through urine or bile. The process of drug metabolism can be broadly categorized into two phases: Phase I and Phase II metabolism. Phase I metabolism typically involves oxidation, reduction, or hydrolysis reactions, mediated mainly by enzymes such as cytochrome P450 (CYP) enzymes. These reactions often introduce or expose functional groups on the drug molecule, rendering it more amenable to subsequent modification. Following Phase I metabolism, Phase II reactions involve the conjugation of the drug or its metabolites with endogenous molecules such as glucuronic acid, sulfate, or amino acids. This conjugation process enhances the water solubility of the drug metabolites, facilitating their elimination via urine or bile. Enzymes such as UDP-glucuronosyltransferases (UGTs) and sulfotransferases are pivotal in Phase II metabolism. The interplay between Phase I and Phase II metabolism ensures efficient drug elimination while often producing metabolites with altered pharmacological activity. However, it's essential to note that drug metabolism can vary significantly among individuals due to genetic factors, environmental influences, and concurrent medications.
Title : Biotech innovations: Bioengineering potential for novel biomanufacturing systems
Murray Moo Young, University of Waterloo, Canada
Title : Targeting noncanonical epitopes in anti-cancer immunotherapy
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Eliminating implant infection: 30,000 nanotextured implants in humans with no failure
Thomas J Webster, Interstellar Therapeutics, United States
Title : Stem cell therapy: An affordable healthcare therapy for various diseases
Anant Marathe, Total Potential Cells (P) Ltd, India
Title : Information leakage: Types, remedies, and open problems
Julia Sidorova, Centro de Investigación Biomédica En Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
Title : Development and characterization of exo-ITC: A fibrous bilayer exosome delivery system for dermatological applications
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico